simple hyperplasia. No inflammatory disorders of female genital trac
Conditions
Interventions
Intervention 1: He first group will be prescribed 40 milligram of Megestrol acetate (40 milligram BRENDOCARE tablet, made by Aburaihan pharmaceutical co. Iran) for two weeks in each month (A 40 millig
Treatment - Drugs
He first group will be prescribed 40 milligram of Megestrol acetate (40 milligram BRENDOCARE tablet, made by Aburaihan pharmaceutical co. Iran) for two weeks in each month (A 40 milligram tablet per d
The second group will be prescribed 2.5 milligram of Letrozole (2.5 milligram Letrax tablet, made by Aburaihan pharmaceutical co. Iran), for two months, A tablet per day. After the end of treatment, a
Sponsors
Vice Chancellor for Research and Technology, Semnan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
44 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age 44 to 50 years, Having abnormal uterine Hemorrhage, simple hyperplasia without Atypia present in the endometrial biopsy, agreement to take part in the study, abnormal thickening of the endometrium (more than 12millimeterin reproductive age sand the pre- menopausal or the presence of endometrium 5 to 12millimeters in reproductive ages and pre- menopausal along with abnormal bleeding continuation despite medical treatment) intrans vaginal ultrasound(first evaluation via basic trans-vaginal ultrasound will be done for all research units by the sonography and in case of abnormal endometrium thickness (more than12millimeters), these people will inter the study; Exclusion criteria: Performing hormone therapy during the last 6 months, wanting to get pregnantfor at least 3 months from now, focal endometrial lesions such as Leiomyoma, having Atypi color complexly perplasia, flushing symptoms, Sleep Disorders, mood changes during the last 3 months, Breast-feeding, Having congenital uterine disorders, Hypothyroidism, Hypertension, history of vascular disease or clotting disorders, sensitivity to Progestin’s.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial hyperplasia without Atypia simple cytologic. Timepoint: Before and after the intervening. Method of measurement: Trans-vaginal ultra sound and endometrial biopsy basis.;Abnormal uterine bleeding. Timepoint: Before and after the interference(the twentieth to twenty fourth day of menstrual cycle). Method of measurement: Trans-vaginal ultra sound and endometrial biopsy basis.;Premenopausal. Timepoint: Before and after the interference(20 to 24menstrual cycles). Method of measurement: Measuring the serum level of follicle-stimulating hormone. | — |
Secondary
| Measure | Time frame |
|---|---|
| Estradiol. Timepoint: Before and after the intervention. Method of measurement: Serum levels of Estradiol.;Endometrial thickness. Timepoint: Before and after the intervening. Method of measurement: The wall thickness of the Endometrial based on ultrasound.;Side effects of taking Letrozole and Megestrol acetate. Timepoint: Once per month. Method of measurement: Genera sensitivity, itching, hives and monthly sonography.;Triglyceride. Timepoint: Before and after the intervention. Method of measurement: Blood levels of triglycerides.;Cholesterol. Timepoint: Before and after the intervention. Method of measurement: Blood levels of cholesterol.;Menstrual status. Timepoint: Before and after the intervention. Method of measurement: Oligomenorrhea, Polymenorrhea ,normal. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Niaz Nik Khah
Semnan University of Medical Sciences
Outcome results
None listed